The thesis

Exact Sciences dominates non-invasive colorectal cancer screening through Cologuard, its stool-DNA test with strong clinical adoption and broad insurance coverage. Revenue growth of 325% year over year signals genuine commercial momentum. However, a net margin of negative 640% and a negative price-to-earnings ratio of 95.7x reveal that growth is being purchased at an extraordinary cost. The composite conviction score of 40 out of 100 sits in high-conviction territory by this framework, yet the gap between a DCF intrinsic value of $77 and current trading levels versus the cash burn creates a thesis held in tension — the narrative is compelling, the math is punishing.

Why now

The broader market is cycling into risk-on behavior, with the Nasdaq jumping nearly 500 points on geopolitical de-escalation signals, which historically lifts high-growth, high-loss healthcare names disproportionately. At the same time, the greed index remaining in the fear zone means sentiment has not yet fully repriced Exact Sciences toward its DCF value of $77, leaving a potential rerating window open.

What to watch

Track gross margin trajectory quarter over quarter — the reported 69.69% gross margin is the one structural positive, and any compression signals pricing or mix deterioration that would undermine the path to profitability. Watch for Medicare coverage decisions on competing multi-cancer early detection tests within the next two quarters, as a positive ruling for a rival would directly challenge Cologuard's screening dominance.

Key risks

A net margin of negative 640% means the company is structurally unprofitable at scale, and any deceleration in revenue growth removes the justification for the loss. Competitive risk is acute — colonoscopy reimbursement changes or a rival multi-cancer early detection test gaining Medicare coverage could compress Cologuard's addressable market faster than consensus expects. Macro tightening or a shift back to risk-off rotation would disproportionately punish a cash-burning name with no earnings floor.